Denna webbsida är endast avsedd för läkare och sjukvårdspersonal med förskrivningsrätt.
Resultaten från MONALEESA-2 visar att kombinationsbehandling med Kisqali och letrozol som första linjens behandling resulterade i en överlevnad på över fem år (63,9 månader).
Läs mer...The pandemic has been constantly present for almost a year. Vaccines have been developed at a speed that was unheard of. Looking back at this unusual year – what are the key learnings for the breast cancer care? Welcome to a Nordic webcast
about breast cancer care in the aftermath of the pandemic.
Det är den längsta medianöverlevnad som rapporterats i studier för kvinnor med HR+/HER2- avancerad bröstcancer som ännu inte genomgått klimakteriet. Resultaten presenterades nyligen vid San Antonio Breast Cancer Symposium.
Läs mer...Novartis today announced updated median overall survival (OS) results for Kisqali® (ribociclib) in combination with endocrine therapy, marking the longest survival data ever reported in premenopausal women with hormone receptor positive, human epidermal growth factor receptor-2 negative (HR+HER2-) metastatic breast cancer. The Phase III MONALEESA-7 trial evaluated Kisqali plus endocrine therapy (goserelin plus either an aromatase inhibitor or tamoxifen) as initial treatment compared to endocrine therapy alone in pre- and perimenopausal women with HR+/HER2- metastatic breast cancer. These updated median OS data will be presented today at the 2020 San Antonio Breast Cancer Virtual Symposium.
Läs mer...Novartis announced analyses from two separate trials with Kymriah® (tisagenlecleucel) in patients with certain advanced lymphomas. In the interim analysis of the investigational Phase II ELARA study, Kymriah led to a complete response (CR) in 65% of patients with relapsed or refractory (r/r) follicular lymphoma (FL) and an overall response rate (ORR) of 83% after at least three months of follow-up.
Läs mer...
